Paper Details

  1. Home
  2. Paper Details

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

Author: BargalloXavier, BlancoJosé Luis, García-CriadoAngeles, GatellJosep M, LagunoMontserrat, LarrousseMaría, LeónAgathe, LoncáMontserrat, MallolasJosep, MartínezEsteban, MilinkovicAna, MiquelRosa, MurillasJavier, Sánchez-TapiasJosé M, de LazzariElisa

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Pegylated interferon alfa-2b (PEG-INF) + ribavirin (RBV) was significantly more effective than interferon alfa-2b (IFN) + RBV for the treatment of chronic hepatitis C in HIV co-infected patients, especially those with genotype 1 or 4.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Current therapies for chronic hepatitis C virus (HCV) in HIV co-infected patients have a low success rate and are poorly tolerated. We have evaluated the efficacy and safety of interferon alfa-2b (IFN) + ribavirin (RBV) versus pegylated interferon alfa-2b (PEG-INF) + RBV. METHODS: Rando...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/00002030-200409030-00003

データ提供：米国国立医学図書館（NLM）

Peginterferon Alfa-2b Plus Ribavirin for HIV/HCV Co-infection

The challenge of treating chronic hepatitis C virus (HCV) in individuals co-infected with HIV is significant. This study aimed to compare the efficacy and safety of two different interferon-based regimens: interferon alfa-2b (IFN) plus ribavirin (RBV) versus pegylated interferon alfa-2b (PEG-IFN) plus RBV. The researchers conducted a randomized, open-label clinical trial with the primary endpoint being a sustained virological response (SVR), indicating the clearance of HCV from the body.

Peginterferon Alfa-2b Shows Superior Efficacy

The study's results, like a clear path emerging from a sandstorm, reveal a significant difference in efficacy between the two treatment regimens. Patients treated with PEG-IFN plus RBV achieved a significantly higher SVR rate compared to those receiving IFN plus RBV. This outcome, like a shimmering oasis in a vast desert, highlights the potential of PEG-IFN as a more effective treatment for HCV in HIV co-infected patients.

Managing HCV in HIV Co-infection

The findings from this study are a reminder that, while there is no one-size-fits-all approach to managing HCV in HIV co-infection, PEG-IFN plus RBV appears to be a promising option. It's crucial to discuss treatment options with a healthcare professional to determine the best course of action based on individual factors. Maintaining a healthy lifestyle, including a nutritious diet and regular exercise, can contribute to overall well-being and support the effectiveness of antiviral therapy.

Dr. Camel's Conclusion

This research, like a wise camel navigating a treacherous desert, unveils the potential of PEG-IFN plus RBV for improving treatment outcomes for HCV in HIV co-infected individuals. It's a journey of discovery, with each step bringing us closer to a future where these complex conditions can be managed more effectively. Like a caravan sharing resources and support, a collaborative approach between healthcare professionals and patients is essential for optimal outcomes.

Date :
  1. Date Completed 2004-11-22
  2. Date Revised 2019-07-18
Further Info :

Pubmed ID

15316335

DOI: Digital Object Identifier

10.1097/00002030-200409030-00003

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.